Overview

Efficacy and Safety of Sintilimab Combined Intraperitoneal and Intravenous Paclitaxel Plus Oral S-1 in Gastric Cancer Patients With Peritoneal Metastasis

Status:
Recruiting

Trial end date:
2023-12-01

Target enrollment:

Participant gender:

Summary

In this phase 2 study, we combined sintilimab, paclitaxel and S-1 as regimen to treat gastric cancer patients with peritoneal metastasis. We are aim to estimate the efficacy and safety of this regimen in the phase 2 study.

Phase:

Phase 2

Details

Lead Sponsor:

Ruijin Hospital

Treatments:

Paclitaxel